EnClear bags $10m to start first in-human

Longevity start-up EnClear Therapies targets neurodegenerative disease with therapeutic filtration technology - Anthony DePasqua

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

We talk exclusively with the Longevity start-up targeting neurodegenerative disease with novel therapeutic filtration (device) technology.

Its mission: access and control cerebrospinal fluid to get access and control of the central nervous system for drug delivery and therapeutics.

Cambridge, MA based EnClear Therapies today announced a $10 million Series A financing that will bring its device-based therapy for treatment of neurodegenerative disease to its first-in-human clinical trial for Amyotrophic Lateral Sclerosis (ALS).

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE